Byron Robinson
Equibles does not estimate personal net worth.
About Byron Robinson
Janux Therapeutics, Inc. reported in an 8-K filed September 19, 2025 that Byron Robinson was terminated as Chief Strategy Officer, effective September 18, 2025. The proxy statement of Janux Therapeutics, Inc. reports total compensation of $5,063,635 for Byron Robinson in fiscal 2025, including a base salary of $362,728. Disclosed compensation is on record for 5 fiscal years.
“Byron Robinson, Ph.D., previously a named executive officer of Janux Therapeutics, Inc. (the “Company”), ceased to serve as Chief Strategy Officer of the Company and departed from the Company effective September 18, 2025 under circumstances that the Company determined to constitute a termination without “Cause” under the terms of the Company’s Change in Control and Severance Benefit Plan (a copy of which is filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1 (File No. 333-256297), filed with the Securities and Exchange Commission on May 19, 2021).”
Affiliation history
-
Janux Therapeutics, Inc. (JANX)
Proxy statement
Start not stated–2025-09-18
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Janux Therapeutics, Inc. (JANX) | Ph.D., J.D. Former Chief Strategy Officer | $362,728 | $5,063,635 |
| 2024 | Janux Therapeutics, Inc. (JANX) | Ph.D., J.D. Chief Strategy Officer | $485,000 | $3,815,641 |
| 2023 | Janux Therapeutics, Inc. (JANX) | Ph.D., J.D. Chief Strategy Officer | $450,000 | $1,740,990 |
| 2022 | Janux Therapeutics, Inc. (JANX) | Ph.D., J.D. Chief Strategic Officer | $351,945 | $3,367,790 |
| 2021 | Janux Therapeutics, Inc. (JANX) | Ph.D., J.D. Chief Strategy Officer | — | — |